[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554889":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":38,"locations":45,"responsibleParty":62,"collaborators":29,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":29,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":48,"whyStopped":29,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 Women on estrogen-progestin contraception","EXPERIMENTAL","For women on estrogen-progestin contraception:\n\n* Correct use of the estrogen-progestin pill in accordance with AMM Or wearing a vaginal ring according to AMM protocol Or wearing a contraceptive skin patch according to AMM protocol\n* Regular cycles of 26 to 33 days",[13,14,15],"Other: Questionnaire","Other: Beighton test","Other: Lachman Test",{"label":17,"type":10,"description":18,"interventionNames":19},"Group 2 Women on progestogen contraception","For women on progestin-only contraception:\n\no Continuous use of the micro-progestogen or progestogen pill Or subcutaneous hormonal implant, Or a progesterone intrauterine device Or dienogest-type contraception",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Group 3 Women without hormonal contraception","For women without hormonal contraception :\n\n* No method of contraception Or copper intrauterine device\n* Regular cycles of 26 to 33 days",[13,14,15],[25,30,34],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Questionnaire","Questionnaires on contraception and sports activities",[9,17,21],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Beighton test","A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.",[9,17,21],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Lachman Test","To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.\n\nThis test is positive if you feel a soft or limp end or if the anterior part.",[9,17,21],[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Pierre-Alexis GAUCI","CONTACT","04 92 03 61 90","+33","gauci.pa@chu-nice.fr",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"CHU Nice - Hôpital de l'Archet 2","RECRUITING","Nice","Alpes-Maritimes","06200","France","FR",{"type":55,"coordinates":56},"Point",[57,58],7.26608,43.70313,{"lat":58,"lon":57},[61],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"type":63,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100554889","evaluation-of-anterior-tibial-knee-translation-in-healthy-women-with-and-without-hormone-therapy-100554889",false,"NCT06504953","Evaluation of Anterior Tibial Knee Translation in Healthy Women With and Without Hormone Therapy","LAX","Inclusion Criteria:\n\n* Female between 18 and 40 years of age;\n* No history of surgery on the 2 lower limbs;\n* No change in contraceptive method in the last 6 months;\n* Signature of informed consent ;\n* Social security affiliation;\n* D14 of her menstrual cycle (+\u002F-1 day) (the first day of the cycle (D1) being considered as the first day of menstruation), except for those on unregulated micro-progestogen contraception.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding (check with urine pregnancy test);\n* Menopause;\n* Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy;\n* History of inflammatory joint disease, systemic or localized to the knee;\n* History of microcrystalline or infectious pathology localized to the knee;\n* History of fracture, severe sprain or dislocation of the knee joint;\n* History of osteoarticular or congenital diseases that may lead to ACL laxity (e.g. Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome, etc.);\n* Signs of hyperlaxity (Beighton test \\> 4);\n* BMI \\> 25 ;\n* Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day);\n* Intense or unusual physical exercise during the last 72 hours before the inclusion visit;\n* Inability to understand the protocol;\n* Women under guardianship, curatorship or deprived of liberty.",true,"FEMALE","18 Years","40 Years",{"count":76,"type":77},90,"ESTIMATED","INTERVENTIONAL",[80],"NA","Women are recognized as being at greater risk of ACL injury, with a risk 6 times higher than that of men. Hyperlaxity is a risk factor for ACL injury, but the pathophysiological basis for this is poorly studied. Hormonal impregnation and certain periods of the menstrual cycle (ovulatory phase) are risk factors for ACL injury. It therefore seems interesting to study the influence of hormonal impregnation on ligament laxity. To date, to our knowledge, no study has investigated such a relationship.",[83,84,85],"Women","Tibial Translation","Hormone",[87,88,89,90],"hormonale","anterior tibial translation","knee","anterior cruciate ligament","2025-10-01",{"date":93,"type":94},"2025-10-02","ACTUAL",{"date":96,"type":94},"2024-08-01",{"date":98,"type":77},"2026-08",{"name":5,"class":6},1]